Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi-database, non-interventional post-authorization safety study

Rachael Williams*, Frank de Vries, Wolfgang Kothny, Carmen Serban, Sandra Lopez-Leon, Changan Chu, Raymond Schlienger

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Web of Science)
Original languageEnglish
Pages (from-to)1473-1478
Number of pages6
JournalDiabetes Obesity & Metabolism
Issue number10
Publication statusPublished - Oct 2017


  • cardiovascular disease
  • DPP-4 inhibitor
  • observational study
  • type 2 diabetes
  • vildagliptin

Cite this